EGFR and non-small cell lung carcinoma: A good PS score (Hazard Ratio 1.691, 95% CI 1.107 to 2.582, p = 0.015, Fig. 1a), recurrent disease (Hazard Ratio 1.524, 95% CI 1.205 to 1.927, p < 0.001, Fig. 1b), EGFR mutations (Hazard Ratio 1.717, 95% CI 1.358 to 2.171, p < 0.001, Fig. 1c), and receiving EGFR-TKI therapy (Hazard Ratio 1.445, 95% CI 1.170 to 1.786, p < 0.001, Fig. 1d) were independent predictors of OS for all patients with NSCLC (Table 2).